JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

Novartis AG

Suletud

116.79 0.8

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

116.52

Max

116.9

Põhinäitajad

By Trading Economics

Sissetulek

418M

4B

Müük

660M

14B

P/E

Sektori keskmine

16.809

34.393

Aktsiakasum

2.42

Dividenditootlus

3.46

Kasumimarginaal

28.18

Töötajad

75,883

EBITDA

-5.8B

4.9M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+5.92% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.46%

2.54%

Turustatistika

By TradingEconomics

Turukapital

-11B

228B

Eelmine avamishind

115.99

Eelmine sulgemishind

116.79

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Novartis AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. aug 2025, 05:47 UTC

Omandamised, ülevõtmised, äriostud

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17. juuli 2025, 14:26 UTC

Tulu

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17. juuli 2025, 06:49 UTC

Tulu

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17. juuli 2025, 05:41 UTC

Tulu

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

8. aug 2025, 11:26 UTC

Market Talk

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8. aug 2025, 11:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8. aug 2025, 10:51 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5. aug 2025, 10:40 UTC

Market Talk

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17. juuli 2025, 11:36 UTC

Market Talk

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17. juuli 2025, 11:26 UTC

Market Talk

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17. juuli 2025, 07:14 UTC

Market Talk

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17. juuli 2025, 07:02 UTC

Market Talk
Tulu

Novartis's Results Look Impressive -- Market Talk

17. juuli 2025, 05:09 UTC

Tulu

Novartis 2Q Sales Grew 11% at Constant Currency

17. juuli 2025, 05:08 UTC

Tulu

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17. juuli 2025, 05:06 UTC

Tulu

Novartis: Mehta's Appointment Is Effective March 2026

17. juuli 2025, 05:05 UTC

Tulu

Novartis: Harry Kirsch Retires After 22 Years With Company

17. juuli 2025, 05:05 UTC

Tulu

Novartis Names Mukul Mehta as CFO

17. juuli 2025, 05:04 UTC

Tulu

Analysts Saw Novartis 2Q Net Profit at $3.815B

17. juuli 2025, 05:04 UTC

Tulu

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17. juuli 2025, 05:04 UTC

Tulu

Analysts Saw Novartis 2Q Sales at $14.17B

17. juuli 2025, 05:04 UTC

Tulu

Novartis 2Q Core Operating Profit $5.925B

17. juuli 2025, 05:04 UTC

Tulu

Novartis 2Q Oper Pft $4.86B

17. juuli 2025, 05:03 UTC

Tulu

Novartis 2Q Sales $14.05B

17. juuli 2025, 05:01 UTC

Tulu

Novartis: Buyback to Be Completed by End of 2027

17. juuli 2025, 05:01 UTC

Tulu

Novartis Starting Buyback of Up to $10B

17. juuli 2025, 05:01 UTC

Tulu

Novartis Backs 2025 Sales View

17. juuli 2025, 05:01 UTC

Tulu

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17. juuli 2025, 05:01 UTC

Tulu

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17. juuli 2025, 05:00 UTC

Tulu

Novartis Raises 2025 Earnings View

17. juuli 2025, 05:00 UTC

Tulu

Novartis AG 2Q Adj EPS $2.42

Võrdlus sarnastega

Hinnamuutus

Novartis AG Prognoos

Hinnasiht

By TipRanks

5.92% tõus

12 kuu keskmine prognoos

Keskmine 122.78 USD  5.92%

Kõrge 137.561 USD

Madal 108 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Novartis AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

0

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 112.63Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.